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ABSTRACT
Alkylating agents are commonly used to treat cancer. Although base excision 
repair (BER) is a major pathway for repairing DNA alkylation damage, under certain 
conditions, the initiation of BER produces toxic repair intermediates that damage healthy 
tissues. The initiation of BER by the alkyladenine DNA glycosylase (AAG, a.k.a. MPG)  
can mediate alkylation-induced cytotoxicity in specific cells in the retina and 
cerebellum of male mice. Cytotoxicity in both wild-type and Aag-transgenic (AagTg) 
mice is abrogated in the absence of Poly(ADP-ribose) polymerase-1 (PARP1). Here, 
we tested whether PARP inhibitors can also prevent alkylation-induced retinal and 
cerebellar degeneration in male and female WT and AagTg mice. Importantly, we 
found that WT mice display sex-dependent alkylation-induced retinal damage (but not 
cerebellar damage), with WT males being more sensitive than females. Accordingly, 
estradiol treatment protects males against alkylation-induced retinal degeneration. 
In AagTg male and female mice, the alkylation-induced tissue damage in both the 
retina and cerebellum is exacerbated and the sex difference in the retina is abolished. 
PARP inhibitors, much like Parp1 gene deletion, protect against alkylation-induced 
AAG-dependent neuronal degeneration in WT and AagTg mice, regardless of the 
gender, but their efficacy in preventing alkylation-induced neuronal degeneration 
depends on PARP inhibitor characteristics and doses. The recent surge in the use of 
PARP inhibitors in combination with cancer chemotherapeutic alkylating agents might 
represent a powerful tool for obtaining increased therapeutic efficacy while avoiding 
the collateral effects of alkylating agents in healthy tissues.
INTRODUCTION
DNA damage is continually induced by environmental 
agents and chemically reactive byproducts of normal cellular 
metabolism. Moreover, DNA damage is often deliberately 
induced during the course of cancer chemotherapy. 
One class of commonly-utilized chemotherapy agents 
is alkylating agents, a broad group of compounds that 
add alkyl groups to DNA. Alkylating agents generate 
numerous types of alkylated DNA base lesions, including 
O6-methylguanine (O6meG), 7-methylguanine (7meG) and 
3-methyladenine (3meA). The effectiveness of alkylators 
as cancer chemotherapeutic agents relies on the induction 
of cell death in rapidly dividing tumor cells by toxic DNA 
lesions that interfere with DNA replication and RNA 
transcription. DNA repair pathways have evolved to cope 
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with recurring DNA damage and, for the most part, provide 
protection in healthy tissues. The base excision repair (BER) 
pathway repairs a variety of alkylated DNA bases [1, 2], and 
the AAG DNA glycosylase (a.k.a. MPG) initiates BER by 
recognizing and excising 7meG and 3meA. Following base 
excision, an apurinic/apyrimidinic endonuclease (APE1) 
hydrolyzes the phosphodiester backbone at the abasic site, 
generating a single-stranded DNA break (SSB) with 3'OH 
and 5'deoxyribose-5-phosphate (5'dRP) termini. DNA 
polymerase ß (Pol ß) removes the 5'dRP terminus and 
conducts single-nucleotide gap filling synthesis. BER is 
completed upon ligation of the nicked DNA by DNA Ligase 
I or the Xrcc1/Ligase IIIα complex. Poly(ADP-ribose) 
polymerase 1 (PARP1, a.k.a. ADP-Ribosyltransferase1/
ADPRT1 or ADP-Ribosyltransferase Diphtheria Toxin-Like 
1/ARTD1) is a multi-functional protein that mediates several 
cellular processes and plays an important role in BER [3–
12]. PARP1 acts as a SSB sensor, and, upon binding a SSB 
containing a 5'dRP terminus, is activated to use NAD+ to 
catalyze the addition of long branched polymers of ADP-
ribose (PAR) to several nuclear proteins, including itself, 
DNA polymerases, DNA ligases, transcription factors and 
histones [9, 13, 14]. PARylation of histones, PARP1, and 
chromatin remodeling enzymes serves to relax chromatin, 
allowing DNA repair proteins access to DNA damage 
[15–17]. Moreover, PARP1 auto-modification is thought 
to recruit XRCC1, the BER scaffold protein that facilitates 
the formation of a complex of BER enzymes, including 
Pol ß and DNA Ligase III [18–20]. With the completion 
of repair, PARP1 dissociates from the DNA and PAR is 
rapidly cleaved, primarily by PAR glycohydrolase [21]. 
Taken together, these aspects of PARP1’s function serve to 
facilitate BER, allowing cells to recover from DNA damage.
Although BER can efficiently repair DNA alkylation 
damage in most cells, in certain cell types, the initiation 
of BER can generate toxic repair intermediates that cause 
damage to healthy tissues. Both SSBs and AP sites exert 
their toxicity as a function of blocking transcription 
and replication [22] and by generating mutations via 
translesion DNA synthesis [23–26]. Further, large 
numbers of SSBs can indirectly induce toxicity through 
hyperactivation of PARP1. Indeed, PARP1 can act as 
a cell death mediator [27, 28]; upon excessive DNA 
damage, PARP1 hyperactivation vastly increases NAD+ 
consumption, resulting in depletion of both NAD+ and 
ATP, such that cells succumb to bioenergetic failure and 
necrotic cell death [27, 29, 30]. Independent of NAD+/
ATP depletion, the PAR polymer inhibits the hexokinase 
1, resulting in the block of glycolysis with consequent 
energy collapse and cell death [31]. The PAR polymer can 
also promote cell death by facilitating translocation of the 
apoptosis inducing factor (AIF) from mitochondria to the 
nucleus, resulting in chromatin condensation, caspase-
independent DNA degradation, and ultimately cell death 
[32–34]. Therefore, although BER is essential for the 
repair of many different types of DNA damage, it must be 
carefully regulated to avoid any imbalance and consequent 
accumulation of toxic BER intermediates.
Recently, using mouse genetic models, we 
demonstrated the importance of both AAG and PARP1 in 
modulating in vivo alkylation toxicity in healthy tissues. 
The alkylating agent, methyl methanesulfonate (MMS), 
induces tissue damage in a specific subset of tissues, 
including retina and cerebellum [35, 36], in WT male 
mice. Modest increases in AAG activity in a transgenic 
mouse model (AagTg mice) increase (rather than decrease) 
susceptibility to the alkylating agent for both whole-animal 
survival and for tissue damage [35, 36]. In the absence of 
AAG activity, these tissues are remarkably refractory to 
MMS-induced cell death. The AAG-mediated alkylation 
sensitivity in the retina and cerebellum, for both wild-type 
(WT) and AagTg mice, is entirely PARP1-dependent, 
being wholly prevented in the absence of PARP1 resulting 
from a null mutation in the Parp1 gene.
Several PARP inhibitors have been developed, 
with some in advanced clinical trials for the treatment of 
various tumors, either alone or in combination with other 
chemotherapeutics [37, 38]. These include Veliparib and 
Olaparib, whose structures contain a nicotinamide moiety 
that competes with NAD+ for PARP binding, making 
them efficient catalytic inhibitors of PARP. In addition to 
catalytic inhibition, the potency of PARP inhibitors also 
depends on their DNA trapping ability [39]. It turns out 
that PARP inhibitors can trap PARP1 on DNA, forming 
complexes that interfere with replication and transcription 
[39–45]. In the presence of PARP inhibitors, PARP1 
still binds to SSBs, but auto-PARylation is prevented; 
inhibited PARP1 thus becomes trapped on the BER 
intermediates. The trapped/inhibited PARP1 complex 
eventually leads to stalled replication forks, accumulation 
of double-strand breaks (DSB) and cell death. Hence, 
PARP inhibitors can have opposite effects: (i) promote 
cell death by diminishing BER or by trapping PARP1 on 
DNA, leading to the induction of DSBs; (ii) prevent cell 
death by avoiding PARP1 hyperactivation and NAD+/ATP 
depletion.
Here, we tested whether the MMS-induced neuronal 
degeneration in WT and AagTg mice would be inhibited 
or exacerbated by the PARP inhibitors, Veliparib and 
Olpaparib. Since gender differences have been reported 
in response to Parp1 deletion and PARP inhibition [46–
50], we included both male and female mice in this study. 
Importantly, we found that WT retinal photoreceptor 
tissue (but not cerebellar tissue) displays sex-dependent 
alkylation-induced damage, with WT males being more 
sensitive than females; this sex difference in alkylation-
induced tissue damage is abolished when AAG levels 
are increased above physiological levels in AagTg mice. 
Moreover, we show that Olaparib and Veliparib, like 
the Parp1 gene deletion, protect against MMS-induced 
AAG-dependent retinal and cerebellar damage in both 
WT and AagTg mice, regardless of gender. Overall, 
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our findings further underscore the recent push for 
investigation and understanding of sex differences in 
diseases where pathophysiological mechanisms involve 
PARP1. Moreover, our data are of particular relevance, 
given the wide range of AAG activity in the human 
population that we and others have reported [35, 51, 
52]. Neuronal degeneration may represent potential 
collateral damage when alkylating agents are used for 
chemotherapy, especially for patients with high AAG 
activity. The recent surge in the use of PARP inhibitors in 
combination with alkylating agents [37, 38] may represent 
a powerful tool for obtaining better therapeutic efficacy in 
cancer treatment, while avoiding the collateral effects of 
alkylation damage in healthy tissues.
RESULTS
Treatment with PARP inhibitors protects against 
MMS-induced retinal degeneration
We have shown that the AAG DNA glycosylase, 
an enzyme that initiates BER, drives alkylation-induced 
cytotoxicity in retinal photoreceptors in WT mice and in 
a transgenic mouse model (AagTg) expressing increased 
levels of AAG [35, 36]. Compared to WT mice, retinal 
photoreceptors display increased alkylation sensitivity 
in AagTg mice and remarkable resistance in Aag-/- mice 
[35]. This AAG-mediated alkylation sensitivity, for both 
WT and AagTg mice, is entirely PARP1-dependent, being 
completely suppressed by Parp1 gene deletion [35]. To 
determine whether drug-mediated PARP inhibition also 
protects against alkylation-induced retinal degeneration, 
we treated WT and AagTg mice with either Veliparib 
(10 mg/kg) or Olaparib (50 mg/kg) 1 hour prior to MMS 
injection (75 mg/kg), and then analyzed retinas 7 days 
(d) post-MMS. Gender differences have been reported in 
response to both Parp1 deletion and PARP inhibition [46–
50]; moreover, differences between Parp1 deletion versus 
PARP inhibition have also been described [53, 54]. We, 
therefore, grouped the results by gender and compared the 
effects of PARP inhibition in MMS-treated WT, AagTg, 
Parp1-/- and AagTg/Parp1-/- mice.
MMS induces selective degeneration of the 
photoreceptor cells located in the outer nuclear layer 
(ONL) of the retina [35, 36]. Retinal degeneration was 
quantified by counting the rows of photoreceptor nuclei 
in the ONL on stained histological sections, as described 
in the Materials and Methods. For all the genotypes, 
untreated male and female mice have about 11 rows 
of photoreceptor nuclei. MMS-treated WT males had 
significantly fewer rows of photoreceptor nuclei, as 
described previously (Figure 1) [35, 36]; it should be noted 
that all our previous studies used male mice exclusively. 
Here, we found that WT female mice were partially 
protected from MMS-induced retinal degeneration 
compared to male mice (5.2 ± 0.5 rows in females versus 
3.1 ± 0.3 rows in males, p = 0.01, Figure 1). Veliparib 
treatment partially protected WT mice from MMS-induced 
retinal degeneration regardless of gender (6.2 ± 0.6 rows 
in males and 7.8 ± 0.6 in females, Figure 1). In contrast, 
Olaparib treatment did not protect either male or female 
WT mice (3.5 ± 0.5, males; 5.8 ± 0.6, females; Figure 1). 
Veliparib or Olaparib treatment itself induced no retinal 
damage (Supplementary Figures 1 and 2). Parp1 gene 
deletion completely rescued the MMS-induced retinal 
degeneration in male mice, as seen previously [35], and in 
female Parp1-/- mice as well (Figure 1).
By comparison with WT, AagTg mice showed 
extreme retinal sensitivity to MMS treatment, as described 
previously [35, 36] (Figure 2). Importantly, no difference 
in MMS sensitivity was observed between male and 
female AagTg mice (1.6 ± 0.2 versus 1.7 ± 0.1, Figure 2). 
Veliparib treatment partially protected AagTg mice from 
MMS-induced retinal degeneration, regardless of gender 
(Figure 2). Notably, protection in AagTg female mice was 
more robust than in AagTg male (7.6 ± 0.5 in females 
versus 4.5 ± 0.4 in males, p < 0.0001). In contrast to what 
we observed in WT, Olaparib treatment partially protected 
both male and female AagTg mice (4.0 ± 0.6, p = 0.002 
and 5.7 ± 0.4, p < 0.0001, respectively). As with Veliparib, 
protection in Olaparib-treated AagTg female mice was 
slightly more robust than in Olaparib-treated AagTg males 
(5.8 ± 0.4 in females versus 4.0 ± 0.6 in males, p = 0.07; 
Figure 2). Greater protection was observed in Veliparib-
treated AagTg female mice as compared with Olaparib-
treated AagTg female mice (7.6 ± 0.5 versus 5.7 ± 0.4, p 
= 0.045; Figure 2). Parp1 gene deletion in AagTg mice 
(Parp1-/-/AagTg) completely rescued the MMS-induced 
retinal degeneration, regardless of gender (Figure 2).
Additional groups of mice were treated with PARP 
inhibitors 1 hour pre- and 24 hours post-MMS injection. 
Combined pre- and post-MMS treatments with PARP 
inhibitors (represented as x2 in Supplementary Figures 
1 and 2) showed results similar to those obtained with 
a single pre-MMS treatment, and no additional retinal 
protection was observed (Supplementary Figures 1 and 
2). Instead, retinal protection was significantly reduced in 
AagTg females treated with Veliparib pre- and post-MMS, 
as compared to AagTg females that received one dose of 
Veliparib pre-MMS (5.0 ± 0.7 vs 7.7 ± 0.5, p < 0.05).
Our findings demonstrate the following: (i) 
the retina displays sex-dependent alkylation-induced 
degeneration with males being more susceptible than 
females; (ii) the difference in response between males 
and females is abolished when AAG levels are increased; 
(iii) PARP inhibitors protect against MMS-induced AAG-
dependent retinal degeneration but, unlike with the Parp1 
deletion, the degree of PARP inhibitor-mediated protection 
depends on the specific PARP inhibitor used, AAG levels 
and mouse gender.
MMS treatment causes significant weight loss in 
both male and female AagTg mice at 24 hours post-
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treatment, regardless of gender, an effect that is not 
observed in WT mice (Supplementary Figure 3) [35, 
55]. Indeed, 24 hours post-MMS treatment, the body 
weights (BW) of male and female AagTg mice were 
87.0 ± 0.9% and 89.7 ± 1.4% of their pre-MMS BW, 
respectively. Treatment with Veliparib partially protected 
both male (BW 91.2 ± 0.9%, p = 0.014) and female (BW 
94.9 ± 1.1%, p = 0.014) AagTg mice from this weight 
loss, while Olaparib significantly protected male (BW 
90.9 ± 0.5%, p = 0.001), but not female (91.3 ± 1.4%, 
p = 0.46), AagTg mice. These data further support the 
protective role of PARP inhibitors against MMS-induced 
tissue damage.
Estradiol protects wild-type male mice against 
MMS-induced retinal degeneration
We have shown that WT female mice are partially 
protected against MMS-induced retinal degeneration, as 
compared to male mice. We therefore determined whether 
estrogen treatment in male mice could protect against 
MMS-induced retinal degeneration. We treated male and 
female mice with MMS and delivered daily intraperitoneal 
injections of 17-β estradiol (E2, 50 μg/kg). The first dose 
of E2 was given 2 hours before the single MMS injection, 
and tissues were collected 7 days post-MMS injection. As 
shown in Figure 3, the photoreceptors of male mice are 
more sensitive to MMS than those of female mice (3.3 
± 0.2 rows in males versus 6.8 ± 0.5 rows in females, 
Figure 1: Treatment with PARP inhibitors protects WT mice against sex- and AAG-dependent MMS-induced retinal 
degeneration. (A) Representative H&E-stained images of retinas from WT mice and Parp1-/- mice 7 days after MMS (75 mg/kg) and 
PARP inhibitor (VEL, Veliparib 10 mg/kg; OLA, Olaparib 50 mg/kg) treatment, as indicated. PARP inhibitors were administered to WT 
mice 1 hour prior to MMS treatment. Magnification is 200X (scale bar 50 μm); ONL, outer nuclear layer; INL, inner nuclear layer; GCL, 
ganglion cell layer; CTR, untreated control mice; ♂, males; ♀, females. (B) Quantification of rows of photoreceptor nuclei in the outer 
nuclear layer of WT and Parp1-/- mice 7 days after MMS (75 mg/kg) and PARP inhibitors (VEL, Veliparib 10 mg/kg; OLA, Olaparib 50 
mg/kg) treatment, as indicated. *, p < 0.05; **, P < 0.01; ♂, males; ♀, females.
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p = 0.0001, Figure 3), corroborating the data shown in 
Figure 1. Figure 3 also shows that E2 protected against 
MMS-induced retinal degeneration in male mice, but 
offered no further protection in female mice (6.2 ± 0.3 
rows in males; 6.4 ± 0.5 in females; Figure 3). The sexual 
dimorphism observed in the retina after MMS treatment 
is not due to sex-related differences in Aag expression 
level (Supplementary Figure 4). Our findings suggest a 
protective role for estrogen against alkylation-induced 
retinal degeneration in female mice.
Treatment with PARP inhibitors protects against 
MMS-induced cerebellar degeneration
MMS induces AAG-dependent cell death in 
cerebellar granule cells, which comprise 99% of 
the granular layer of the cerebellum. This cerebellar 
degeneration is completely suppressed by Parp1 
gene deletion [35]. To determine whether PARP 
inhibition protects against alkylation-induced cerebellar 
degeneration, we administered Veliparib (10 mg/kg) or 
Olaparib (50 mg/kg) to both WT and AagTg mice 1 hour 
prior to MMS-injection. Due to the dramatically higher 
MMS sensitivity of AagTg mice compared to WT mice 
and based on our previous published results [35], in order 
to induce the degeneration phenotype such that one could 
accurately quantify the cerebellar degeneration, we used 
different MMS doses for each genotype: 150 mg/kg and 
60 mg/kg in WT and AagTg mice, respectively. Cerebella 
were collected 6 hours post-MMS injection. Cerebellar 
degeneration was then quantified by counting the number 
of pyknotic nuclei in the granular layer of the cerebellum, 
as described in the Materials and Methods. In untreated 
mice, no pyknotic nuclei were observed (Figures 4 and 5). 
However, 6 hours post-MMS, we observed severe lesions 
containing numerous pyknotic nuclei surrounded by white 
Figure 2: Treatment with PARP inhibitors protects AagTg mice against AAG-dependent MMS-induced retinal 
degeneration. (A) Representative H&E-stained images of retinas from AagTg and AagTg/Parp1-/- mice 7 days after MMS (75 mg/kg) 
and PARP inhibitor (VEL, Veliparib 10 mg/kg; OLA, Olaparib 50 mg/kg) treatment, as indicated. PARP inhibitors were administered to 
AagTg mice 1 hour prior to MMS treatment. Magnification is 200X (scale bar 50 μm); ONL, outer nuclear layer; INL, inner nuclear layer; 
GCL, ganglion cell layer; CTR, untreated control mice; ♂, males; ♀, females. (B) Quantification of rows of photoreceptor nuclei in the 
outer nuclear layer of AagTg and AagTg/Parp1-/- mice 7 days after MMS (75 mg/kg) and PARP inhibitor (VEL, Veliparib 10 mg/kg; OLA, 
Olaparib 50 mg/kg) treatment, as indicated. *, p < 0.05; **, P < 0.01; ***, p < 0.001; ♂, males; ♀, females.
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space (edema) in WT mice (Figure 4), as shown previously 
[35]. The number of MMS-induced pyknotic nuclei was 
similar in male and female WT mice (1332 ± 179 in males; 
1753 ± 175 in females, p = 0.11). Veliparib treatment (10 
mg/kg) almost completely rescued WT mice, regardless 
of sex (Figure 4). Conversely, Olaparib, at the dose of 50 
mg/kg, was able to partially protect male, but not female, 
WT mice (514 ± 171 in males and 1325 ± 405 in females; 
Figure 4). Veliparib or Olaparib treatment itself did not 
induce any cerebellar damage (Supplementary Figure 5).
AagTg mice, despite being exposed to a lower 
MMS dose, nevertheless experienced similar or increased 
MMS-induced cerebellar degeneration compared to WT 
mice (2036 ± 238 pyknotic nuclei in AagTg males versus 
1332 ± 179 in WT males, p = 0.03; 1937 ± 254 in AagTg 
females versus 1753 ± 175 in WT females, p = 0.54). 
Veliparib treatment (10 mg/kg) almost completely rescued 
AagTg mice, regardless of gender (Figure 5). Olaparib, at 
the dose of 50 mg/kg, not only did not protect male or 
female AagTg mice, but, remarkably, increased the tissue 
damage in MMS-treated AagTg males while having little 
effect in females (2890 ± 251 in males, p = 0.03; 1632 
± 420 in females, p = 0.53; Figure 5). Administration 
of a much lower Olaparib dose (1 mg/kg) was able to 
significantly protect both male and female AagTg mice 
(Figure 5). Our data suggest that knowledge of PARP 
inhibitor characteristics, with respect to DNA trapping, 
and the use of appropriate doses are crucial in order to 
obtain the desired therapeutic efficacy.
Parp1 gene deletion completely rescued MMS-
induced cerebellar degeneration in both the WT and 
AagTg backgrounds, regardless of gender (Figures 4 and 
5). Our findings demonstrate that: (i) PARP inhibitors can 
protect from MMS-induced cerebellar degeneration; (ii) 
Figure 3: Estradiol protects WT male mice from MMS-induced retinal degeneration. (A) Representative H&E-stained 
images of retinas from WT male and female mice treated with 17-ß estradiol (E2, 50 μg/kg/day) and/or MMS (75 mg/kg), as indicated. 
E2 was injected 2 hours before MMS injection and daily post-MMS injection. Retinas were harvested 7 days post-MMS injection. 
Magnification is 200X (scale bar 50 μm); ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer; ♂, males; ♀, 
females. (B) Quantification of rows of photoreceptor nuclei in the outer nuclear layer of WT male and female mice, treated or not treated 
with E2 (50 μg/kg/day), 7 days post-MMS (75 mg/kg). ***, p < 0.001; ♂, males; ♀, females.
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as in the retina, unlike the Parp1 deletion, the ability of 
PARP inhibitors to protect against MMS-induced AAG-
dependent cerebellar degeneration depends on AAG levels 
and PARP inhibitor properties and doses.
DISCUSSION
We observed a tissue specific sexual dimorphism 
after treatment with an alkylating agent. Specifically, MMS-
treated WT female mice are partially protected against 
retinal degeneration, as compared with WT male mice, 
while both sexes exhibit similar cerebellar degeneration. 
Moreover, treatment of WT male mice with estrogen resulted 
in protection against MMS-induced retinal degeneration, 
providing an explanation for the relative resistance to 
alkylation-induced retinal degeneration in female mice. 
Gender differences in response to Parp1 deletion or PARP 
inhibition were recently reported using mouse models of 
cerebral ischemia, endotoxemia and autoimmune nephritis, 
[46–50, 56]. In particular, it was demonstrated that (i) female 
mouse models are partially resistant to cerebral ischemia, 
endotoxemia and autoimmune nephritis; (ii) treatment of 
male mice with estradiol reduces PARP1 activation and exerts 
a protective effect against cerebral ischemia, endotoxemia 
and autoimmune nephritis [46, 47, 50]; (iii) in the absence 
of functional PARP1, male mice are preferentially protected 
against cerebral ischemia, endotoxemia and autoimmune 
nephritis compared to female mice, in which PARP1 deletion/
inhibition offered no benefit in pathological outcome. PARP1 
has been shown to interact with the estrogen receptor alpha 
(ERα) to form a complex that binds to DNA in vitro [46]. The 
binding of this ERα/PARP1 complex to DNA is enhanced 
by the presence of the estrogen ligand. Thus, it has been 
proposed that, in females, estrogen may anchor the PARP1/
Figure 4: Treatment with PARP inhibitors protects WT mice against AAG-dependent MMS-induced cerebellar 
degeneration. (A) Representative H&E-stained images of cerebellar granular cells from WT and Parp1-/- mice 6 hours after MMS (75 
mg/kg) treatment. PARP inhibitors (VEL, Veliparib 10 mg/kg; OLA, Olaparib, 50 mg/kg) were administered to WT mice 1 hour prior MMS 
treatment, as indicated. Magnification is 600X (scale bar 20 μm); CTR, untreated control mice; ♂, males; ♀, females. (B) Quantification 
of pyknotic nuclei/mm2 in WT and Parp1-/- mice after MMS and PARP inhibitor (VEL, Veliparib 10 mg/kg; OLA, Olaparib 50 mg/kg) 
treatment, as indicated. *, p < 0.05; **, P < 0.01; ***, p < 0.001; ns, not statistically significant (p = 0.11); ♂, males; ♀, females.
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ERα complex to specific regions of DNA, reducing its 
availability to access and bind DNA SSBs, thus reducing 
PARP1 hyperactivation and cell death in the experimental 
models of disease. PARP1 was also shown to bind and 
PARylate ERα, leading to increased binding of ERα to the 
estrogen response element within the promoters of target 
genes, thus promoting ERα-mediated transcription [57]; 
estradiol enhances PARlylation of ERα and ERα-mediated 
transcription. Moreover, ERα is known to interact with other 
proteins involved in BER, namely AAG, FEN-1 and APE1 
[58]. Binding of ERα with these proteins may influence not 
only ERα-mediated transcription, but also the expression or 
function of each protein. Expression of ERα has been reported 
in rodent and human photoreceptors [59, 60]. Together, 
these findings suggest that a direct interaction between BER 
proteins, PARP1 in particular, and estrogen receptors could 
lead to changes in DNA repair, PARP activation and/or gene 
expression. Such changes presumably underlie the sexual 
dimorphism of MMS-mediated retinal degeneration we have 
observed in mice. The known interaction between ERα and 
protein networks involved in cell fate determination and the 
oxidative stress response might also contribute to the sexual 
dimorphism [58]. The protection against alkylation-induced 
retinal degeneration that we observed in estrogen-treated 
male mice further supports the proposed model that ERα/
estrogen and the PARP1/BER pathways interact, and also 
confirms the role of estrogen in protecting against alkylation-
induced retinal degeneration.
In contrast to the retina, cerebellar degeneration 
induced by MMS in WT mice was not sexually dimorphic. 
The fact that ERα expression is lower or absent in the 
cerebellum [61, 62] might explain the lack of sexual 
Figure 5: Treatment with PARP inhibitors protects AagTg mice against AAG-dependent MMS-induced cerebellar 
degeneration. (A) Representative H&E-stained images of cerebellar granular cells from AagTg and AagTg/Parp1-/- mice 6 hours after 
MMS (75 mg/kg) treatment. PARP inhibitors (VEL, Veliparib 10 mg/kg; OLA Hi, Olaparib 50 mg/kg; OLA Lo, Olaparib 1 mg/kg) were 
administered to AagTg mice 1 hour prior MMS treatment. Magnification is 600X (scale bar 20 μm); CTR, untreated control mice; ♂, males; 
♀, females. (B) Quantification of pyknotic nuclei/mm2 in AagTg and AagTg/Parp1-/- mice after MMS and PARP inhibitor (VEL, Veliparib 
10 mg/kg; OLA Hi, Olaparib 50 mg/kg, OLA Lo, Olaparib 1 mg/kg) treatment, as indicated. *, p < 0.05; **, P < 0.01; ***, p < 0.001; ns, 
not statistically significant; ♂, males; ♀, females.
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dimorphism for cerebellar degeneration in MMS-treated 
WT mice. The AagTg mice show increased MMS-induced 
retinal and cerebellar degeneration compared to WT mice, 
as seen previously [35, 36]. Note that we did not observe 
any sexual dimorphism in the retinas of MMS-treated 
AagTg mice; this may be due to the inability of ERα to 
compensate for PARP1 hyperactivation due to the higher 
expression of AAG. In addition, it has been shown that 
interaction between AAG and ERα causes decreased ERα-
mediated transcription and increased AAG catalytic activity 
[63]. Excessive suppression of ERα-mediated transcription 
in AagTg mice might further contribute to the lack of 
sexual dimorphism in the retinas of AagTg mice. Overall, 
our data underscore recent arguments for investigating and 
understanding sex differences in both basic and clinical 
science [64–67]. Furthermore, the sexually dimorphic 
response to alkylation-induced damage underscores the 
importance for sexual-stratification in cancer chemotherapy 
trials, especially those that utilize alkylating agents.
We found that Parp1 gene deletion resulted in 
complete protection against MMS-induced retinal and 
cerebellar degeneration in both WT and AagTg mice, 
regardless of gender. It has been described previously that 
female and male mice exhibit different responses to Parp1 
deletion in other mouse models of disease. Indeed, Parp1 
deletion has been shown to protect male, but not female, 
animals against stroke and autoimmune-nephritis [47-50, 
68]. A sex-specific bias for distinct cell death pathways 
in some tissues might account for the sexually dimorphic 
response to Parp1 deletion observed in these experimental 
models. It appears that, upon specific kinds of stress, 
female cells preferentially activate an apoptotic pathway 
while male cells favor a PARP1-dependent necrotic 
pathway [69–71]. It is well known that DNA alkylating 
agents can induce necrosis in a PARP1-dependent manner, 
although this is likely to be cell type-dependent [72–74]. 
Even though female mice are partially protected against 
alkylation-induced retinal degeneration compared to 
male mice, Parp1 gene deletion completely rescued both 
males and females against alkylation-induced retinal and 
cerebellar degeneration. We hypothesized that alkylation 
treatment induces retinal and cerebellar degeneration via 
the PARP1-dependent necrotic pathway in both males 
and females, but that female photoreceptors are just more 
resistant to such necrosis.
We found that treatment with PARP inhibitors 
also protects against MMS-induced AAG-dependent 
neuronal damage, but their efficacy depends mainly on 
their chemistry and dosage. Indeed, Veliparib, at a dose 
of 10 mg/kg, was able to protect against MMS-induced 
retinal and cerebellar degeneration in both WT and AagTg 
mice regardless of the gender, whereas Olaparib, at a 
dose of 50 mg/kg, was able to significantly protect only 
AagTg mice from retinal degeneration and WT male mice 
from cerebellar degeneration. Moreover, the extent of 
protection after Olaparib treatment was consistently lower 
than that observed after Veliparib treatment. It has been 
shown that, in addition to catalytic inhibition, some PARP 
inhibitors can induce cytotoxic PARP-DNA complexes, 
most likely by enhancing the crosslink between PARP 
and AP sites, or by inducing a PARP conformational 
change that traps PARP at the site of damage [39, 41, 
44, 75]. Such trapping would interfere with DNA repair, 
replication and transcription. The formation of such a 
toxic complex appears to be a suicidal event when BER 
is overwhelmed, as can be the case with MMS treatment 
[41–43]. The potency in trapping PARP differs markedly 
among PARP inhibitors and it is not correlated with 
the catalytic inhibitory properties of each drug [39]. 
Therefore, PARP inhibitors can produce two competing 
effects: (i) resistance to MMS-induced cell death by PARP 
catalytic inhibition that prevents NAD+/ATP depletion, or 
(ii) sensitivity to MMS-induced necrotic cell death by 
trapping of PARP on DNA. Even though Olaparib has a 
higher catalytic inhibition activity, it also has much higher 
PARP-DNA trapping activity compared to Veliparib, 
thus making Olaparib a more potent cytotoxic compound 
than Veliparib [39]. As previously stated, in contrast 
to Veliparib, we observed absent or reduced Olaparib 
protection against MMS-induced neuronal degeneration, 
which may be due to Olaparib’s higher PARP-DNA 
trapping activity. Notably, Olaparib treatment (50 mg/
kg) resulted in increased, rather than decreased, MMS-
induced cerebellar degeneration in AagTg male mice. We 
hypothesize that the increased AAG activity in AagTg 
mice might lead to many more AP sites and SSBs and, 
thus, more substrate for Olaparib PARP-DNA trapping 
activity. Administration of a much lower dose of Olaparib 
(1 mg/kg) in AagTg mice resulted in protection against 
MMS-induced cerebellar degeneration in both males 
and females, supporting our hypothesis and suggesting 
that knowledge of PARP inhibitor properties and use of 
appropriate dosages is necessary to obtain therapeutic 
efficacy. Even so, protection against MMS-induced 
cerebellar degeneration after treatment with low doses 
of Olaparib (1 mg/kg) was still not at the level observed 
after Veliparb treatment (10 mg/kg) further suggesting 
that PARP inhibitors with less trapping activity, such as 
Veliparib, are more efficacious at preventing alkylation-
induced neuronal degeneration. Finally, an additional 
dose of PARP inhibitors 24 hours after MMS treatment 
did not result in increased efficacy for either compound 
and, notably, in the case of Veliparib, resulted in reduced 
protection against retinal degeneration in female AagTg 
mice, suggesting that a single dose pre-MMS treatment 
is sufficient for therapeutic efficacy and additional doses 
may only cause increased damage due to PARP-DNA 
trapping activity.
In addition to protecting against neuronal 
degeneration, PARP inhibitors also protect AagTg mice 
against alkylation-induced body weight loss, regardless 
of the gender. We have shown that AAG mediates 
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MMS-induced whole-animal lethality accompanied by 
cytotoxicity in organs other than retina and cerebellum 
[35]. Therefore, PARP inhibitors might also exert a 
protective effect in several other organs resulting in 
reduced overall weight loss.
Taken together, our data show that low doses of 
PARP inhibitors, or PARP inhibitors with less PARP-DNA 
trapping ability, can protect against alkylation induced 
neuronal degeneration. Alkylating agents are commonly 
used in cancer therapy. It is possible that the alkylation-
induced neuronal degeneration and organ toxicity we 
observed in mice [35, 36] could be a rate-limiting side 
effect of alkylating agents used in cancer chemotherapy. 
Given the wide inter-individual variability of AAG [35, 
51, 52] and PARP1 activity [76] in human populations 
and the sexual dimorphism we observed, toxicity might 
be limited to particular subpopulations, making it difficult 
to generalize. Nevertheless, our findings in mice may 
potentially prove to have important clinical relevance.
PARP inhibitors are used in a clinical setting for the 
treatment of various tumors, either alone or in combination 
with other chemotherapeutics, including alkylating agents 
[37, 38]. PARP inhibitors allow selective killing of cancer 
cells because the trapping/cytotoxic effect makes use of 
deficiencies in DNA repair systems that are unique to 
individual types of cancer (e.g. BRCA1/BRCA2-deficient 
tumors), as compared with normal tissue [40, 77–79]. 
PARP inhibitor cytotoxicity is enhanced when they are 
combined with alkylating agents [41–43]. Therefore, the 
recent surge in the use of PARP inhibitors in combination 
with alkylating agents might represent a powerful tool for 
obtaining better therapeutic efficacy in cancer treatment, 
while avoiding the collateral effects of alkylating agents 
in healthy tissues of the subpopulations mentioned above. 
Moreover, our findings suggest that low doses of PARP 
inhibitors, or PARP inhibitors with less DNA trapping 
ability, might also be used to treat neurodegenerative 
disorders that involve PARP1 activation [80, 81], and that 
it would be worthwhile to identify PARP inhibitors with 
little or no PARP-DNA trapping activity.
MATERIALS AND METHODS
Animals and treatments
Aag transgenic (AagTg) mice were described 
previously [35, 36, 82]. Parp1-/- mice were purchased from 
Jackson Laboratories [83] and backcrossed to C57BL/6. 
WT and AagTg mice were on a C57BL/6 genetic 
background. Parp1-/- and AagTg/Parp1-/-mice were on 
mixed genetic background (C57BL/6:129S). All animal 
procedures were performed according the NIH guide for 
the Care and Use of Laboratory Animals.
MMS was injected intraperitoneally. Veliparib 
(Selleck Chemichals Inc) was administered by oral gavage 
(10 mg/kg) and Olaparib (Selleck Chemicals Inc) by 
intraperitoneal injections (50 mg/kg or 1 mg/kg). PARP 
inhibitor doses were chosen based on datasheet guidelines 
and previously published data [84, 85]. 17-β estradiol (E2, 
Sigma) was injected intraperitoneally. For experiments in 
the retina, where indicated, mice received daily E2 doses 
of 50 μg/kg.
Histological analysis
Eyes were fixed in Carnoy’s fixative and brains in 
10% formalin. Tissues were processed by the Histology 
Core Facility at the David H. Koch Institute for Integrative 
Cancer Research (MIT); they were paraffin-embedded, 
sectioned at 5 μm, and stained with hematoxylin and eosin 
(H&E). All H&E-stained slides were blindly analyzed 
using a Nikon Eclipse 6800 microscope, a Retiga Exi 
camera, Velocity and ImageJ softwares.
To quantify retinal degeneration, the number of rows 
of photoreceptor nuclei in the outer nuclear layer (ONL) of 
each eye was counted. A minimum of three sections, close 
to the optic nerve area, was analyzed for each eye. For 
each section, the number of row of photoreceptor nuclei 
in the ONL was counted at three different points along the 
retina and averaged. The averaged counts for each of the 
three sections were then averaged for each eye. All eyes 
in an experimental group were then averaged and standard 
errors calculated. To quantify cerebellar degeneration, 
images representative of each lobe in the cerebellum 
were taken. For each cerebellum, the number of pyknotic 
nuclei/mm2 in each lobe was counted and then averaged. 
The counts from each group were then averaged, and 
standard errors calculated.
Statistics
Statistical analyses were performed using GraphPad 
Prism software. Statistical significance was determined 
using unpaired t-test. A p-value is considered significant 
if less than 0.05.
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